ArticleiLIVER2023
Free fatty acid-induced miR-22 inhibits gluconeogenesis via SIRT-1-mediated PGC-1α expression in nonalcoholic fatty liver disease.
Article in iLIVER, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Role of microRNA-22 in Metabolism.International journal of molecular sciences · 2025Review
- Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity.World journal of gastroenterology · 2024Article
- The Role of MicroRNAs in Liver Functioning: from Biogenesis to Therapeutic Approaches (Review).Sovremennye tekhnologii v meditsine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Free fatty acids (FFAs) are one of the important regulators of the progression of nonalcoholic fatty liver disease. The FFAs are shown to modulate the metabolic status of the liver by modulating several cellular pathways in hepatocytes. Here, we elucidated the role of miR-22 in modulating FFAs-mediated gluconeogenesis. Methods: Huh7 and WRL68 cells were transfected with nonspecific miRNA, miR-22 premiRs or anti-miR-22 oligos followed by incubation with palmitic acid, oleic acid, and linoleic acid (300 μM each) for 48 and 72 h after transfection. The expression of miR-22 was performed using real-time polymerase chain reaction and Western blots were performed for SIRT-1, PGC-1α, PEPCK, and glucose-6-phosphatase. Three groups of C57BL/6 mice (6 mice per group) were fed with standard diet, choline sufficient l-amino acid defined diet or choline-deficient l-amino acid defined (CDAA) diet for 6, 18, 32, or 54 weeks. Triglycerides content was measured in the serum. Expression of miR-22 and the protein expression of gluconeogenic enzymes were analyzed in the tissue samples. Results: Incubation of miR-22-transfected cells with FFAs inhibited the expression of SIRT-1, PGC-1α, PEPCK, and glucose-6-phosphatase, while miR-22 expression was increased. These changes were reversed when the cells were transfected with anti-miR-22 oligos. CDAA-fed mice showed the significant increase in triglycerides content and miR-22 expression, while there was an inhibition of SIRT-1, PGC-1α, PEPCK, and glucose-6-phosphatase expression in CDAA-fed mice. Conclusions: These data confirm that FFAs inhibited gluconeogenesis via miR-22-mediated inhibition of SIRT-1, which in turn inhibited PGC-1α in hepatic cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.